Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock Position Reduced by Nuveen Asset Management LLC

Nuveen Asset Management LLC reduced its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 39.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 409,637 shares of the company's stock after selling 263,917 shares during the quarter. Nuveen Asset Management LLC owned about 0.54% of Nurix Therapeutics worth $7,718,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. US Bancorp DE lifted its position in shares of Nurix Therapeutics by 144.7% during the 4th quarter. US Bancorp DE now owns 1,424 shares of the company's stock valued at $27,000 after acquiring an additional 842 shares during the period. Aquatic Capital Management LLC purchased a new stake in Nurix Therapeutics during the fourth quarter worth $87,000. Summit Investment Advisors Inc. grew its holdings in Nurix Therapeutics by 13.6% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company's stock valued at $138,000 after purchasing an additional 877 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in shares of Nurix Therapeutics in the fourth quarter valued at $164,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of Nurix Therapeutics during the 4th quarter worth $207,000.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on NRIX. Leerink Partnrs raised shares of Nurix Therapeutics to a "hold" rating in a research note on Monday, March 17th. Morgan Stanley increased their price target on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the company an "equal weight" rating in a research report on Monday, February 3rd. HC Wainwright restated a "buy" rating and set a $36.00 price objective on shares of Nurix Therapeutics in a research report on Wednesday, April 2nd. Needham & Company LLC reiterated a "buy" rating and set a $27.00 target price on shares of Nurix Therapeutics in a report on Tuesday, April 29th. Finally, Wall Street Zen downgraded Nurix Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. One analyst has rated the stock with a sell rating, three have issued a hold rating and sixteen have issued a buy rating to the company's stock. According to MarketBeat.com, Nurix Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $30.44.

Nurix Therapeutics Stock Down 0.5%

Shares of NASDAQ NRIX traded down $0.06 during midday trading on Tuesday, hitting $12.08. The stock had a trading volume of 1,334,613 shares, compared to its average volume of 880,750. Nurix Therapeutics, Inc. has a 1-year low of $8.18 and a 1-year high of $29.56. The company has a fifty day moving average price of $10.33 and a 200 day moving average price of $15.54. The company has a market capitalization of $920.93 million, a price-to-earnings ratio of -4.18 and a beta of 2.23.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its quarterly earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share for the quarter, topping analysts' consensus estimates of ($0.72) by $0.05. Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. The firm had revenue of $18.45 million during the quarter, compared to analysts' expectations of $12.78 million. During the same period in the prior year, the company earned ($0.76) EPS. On average, research analysts forecast that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Insider Activity at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,377 shares of the company's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total value of $38,835.50. Following the completion of the transaction, the insider now directly owns 61,516 shares of the company's stock, valued at $707,434. This represents a 5.20% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Houte Hans Van sold 2,438 shares of Nurix Therapeutics stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total value of $28,037.00. Following the sale, the chief financial officer now directly owns 39,922 shares in the company, valued at approximately $459,103. The trade was a 5.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 12,013 shares of company stock worth $137,096. 7.40% of the stock is currently owned by company insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.